DiaMedica Therapeutics progresses DM199 for ischemic stroke and preeclampsia, aiming to expand treatment windows. Read why ...

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible ...

You may be familiar with the common signs and symptoms of a stroke: loss of vision, drooping face, weak limbs, and slurred ...

Use of recombinant tissue plasminogen activator (alteplase) for treatment of acute ischemic stroke outside the criteria of guidelines and licenses is not uncommon. Most important situations of off ...

Detailed price information for Nervgen Pharma Corp (NGENF) from The Globe and Mail including charting and trades.

Ischemic strokes ... In the years that followed, two treatments emerged for acute stroke patients. Tissue plasminogen activator, or tPA, was approved by the FDA in 1996. Delivered by catheter ...

tissue plasminogen activator. In this study, we examined the interplay among structural racism, urbanity, and the delivery of acute ischemic stroke care in the United States, using validated measures ...

Why This Matters An ischemic stroke happens when a clot blocks blood flow to the brain. Current treatments like clot-busting drugs (tPA) or mechanical thrombectomy (surgically removing the clot ...

can predict successful recanalization following IV thrombolysis with recombinant tissue plasminogen activator. Conflicting and limited data exist regarding the value of assessing thrombus properties ...